EIC Accelerator

Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.

Vivalyx operates a patented organ preservation system designed to enhance the success of organ transplantation. Its technology combines static cold storage with machine perfusion, offering a blood-free alternative that aims to increase the vitality and availability of donor organs, thereby improving patient outcomes.

Vivalyx operates a patented organ preservation system designed to enhance the success of organ transplantation. Its technology combines static cold storage with machine perfusion, offering a blood-free alternative that aims to increase the vitality and availability of donor organs, thereby improving patient outcomes.

Invitris is a biotech company focused on developing protein-based drugs and manufacturing bacteriophages to combat antibiotic-resistant bacteria. The company specializes in synthesizing arbitrary phages within a single system, which allows for effective quality assessment, synthetic phage production, and quality control services. By enabling personalized diagnostics, Invitris aims to provide patients with targeted treatments for bacterial infections, ensuring both safety and practical application in the fight against resistant pathogens.

TetraKit Technologies is a Copenhagen-based company founded in 2021 that specializes in a click chemistry-based radiochemical platform aimed at developing therapeutics for metastatic cancer. The company offers a targeted radionuclide therapy and nuclear imaging platform for cancer diagnosis, utilizing radiopharmaceuticals such as fluorine-18 and astatine-211 for positron emission tomography (PET) imaging and targeted alpha-radionuclide therapy. TetraKit's innovative approach incorporates proprietary click chemistry and a modular design, which allows for rapid and mild labeling conditions across a variety of molecules. This platform enhances the efficiency of production processes in the field of radiopharmaceuticals, enabling medical professionals to leverage advanced technologies in cancer treatment and imaging.

Developer of a revolutionary thrombectomy device designed specifically for treating ischemic stroke. The company's innovative technology enables efficient and safe removal of blood clots from large to small vessels, even in distal regions of the brain, improving patient outcomes.

Robeaute is a research and development agency that develops neurosurgical microrobots that can adapt to different types of medical evidence.

NanoPhoria is a biotechnology company focused on cardiovascular therapies. It develops non-viral, nanoparticle-based drug delivery platforms designed to target the heart directly and improve the delivery of biologics, including peptides and RNAs. The company is pursuing tissue-directed delivery methods and inhalable formulations, with preclinical programs aimed at treating cardiovascular diseases such as heart failure with reduced ejection fraction. Its platform enables selective organ- and cell-level targeting to expand administration routes beyond traditional systemic delivery, supporting research and development to advance cardiovascular health.

Developer of a revolutionary thrombectomy device designed specifically for treating ischemic stroke. The company's innovative technology enables efficient and safe removal of blood clots from large to small vessels, even in distal regions of the brain, improving patient outcomes.

Neurescue ApS, headquartered in Copenhagen, Denmark, specializes in developing innovative medical devices aimed at addressing cardiac arrest and hemorrhage. Established in 2014, the company has introduced its flagship product, the safeREBOA device, which is recognized as the first computer-aided aortic occlusion catheter designed to enhance the care of emergency patients. Neurescue's commitment lies in improving resuscitation rates and extending critical treatment time through advanced cardiovascular solutions. The organization is focused on advancing the clinical utility of its devices to ultimately save lives in emergency situations.

NanoPhoria is a biotechnology company focused on cardiovascular therapies. It develops non-viral, nanoparticle-based drug delivery platforms designed to target the heart directly and improve the delivery of biologics, including peptides and RNAs. The company is pursuing tissue-directed delivery methods and inhalable formulations, with preclinical programs aimed at treating cardiovascular diseases such as heart failure with reduced ejection fraction. Its platform enables selective organ- and cell-level targeting to expand administration routes beyond traditional systemic delivery, supporting research and development to advance cardiovascular health.

Invitris is a biotech company focused on developing protein-based drugs and manufacturing bacteriophages to combat antibiotic-resistant bacteria. The company specializes in synthesizing arbitrary phages within a single system, which allows for effective quality assessment, synthetic phage production, and quality control services. By enabling personalized diagnostics, Invitris aims to provide patients with targeted treatments for bacterial infections, ensuring both safety and practical application in the fight against resistant pathogens.

TetraKit Technologies is a Copenhagen-based company founded in 2021 that specializes in a click chemistry-based radiochemical platform aimed at developing therapeutics for metastatic cancer. The company offers a targeted radionuclide therapy and nuclear imaging platform for cancer diagnosis, utilizing radiopharmaceuticals such as fluorine-18 and astatine-211 for positron emission tomography (PET) imaging and targeted alpha-radionuclide therapy. TetraKit's innovative approach incorporates proprietary click chemistry and a modular design, which allows for rapid and mild labeling conditions across a variety of molecules. This platform enhances the efficiency of production processes in the field of radiopharmaceuticals, enabling medical professionals to leverage advanced technologies in cancer treatment and imaging.

Robeaute is a research and development agency that develops neurosurgical microrobots that can adapt to different types of medical evidence.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

MindPeak GmbH is a technology company based in Hamburg, Germany, founded in 2018. It specializes in developing artificial intelligence software tools aimed at enhancing the accuracy and efficiency of cancer diagnostics. The company's flagship product, BreastAI, is designed for the quantification of breast cancer immunohistochemistry (IHC) and can be integrated into third-party software systems. MindPeak's solutions automate tissue diagnostics, enabling pathologists to identify and quantify tumorous regions and detect breast cancer cells more effectively. By streamlining tasks such as cell and biomarker quantification, MindPeak's tools allow cancer specialists to focus on critical decision-making in clinical environments, ultimately improving patient care while making diagnostic processes more accessible and cost-effective.

BioSourcing is a biotechnology company based in Liège, Belgium, focused on developing a new generation of biotherapeutics, particularly monoclonal antibodies, to address global unmet medical needs. The company employs advanced technologies, including genome editing techniques like CRISPR, to innovate the design of biotherapeutics. This disruptive approach significantly reduces capital requirements and production costs, especially for large-scale manufacturing, while enhancing the quality and efficiency of biopharmaceuticals through improved glycosylation processes. BioSourcing is committed to sustainability, aiming to minimize the carbon footprint associated with biotherapeutic production. The company boasts a team of leading scientists and international experts, supported by strategic partnerships with key players in the pharmaceutical and biotechnology sectors.

BioSourcing is a biotechnology company based in Liège, Belgium, focused on developing a new generation of biotherapeutics, particularly monoclonal antibodies, to address global unmet medical needs. The company employs advanced technologies, including genome editing techniques like CRISPR, to innovate the design of biotherapeutics. This disruptive approach significantly reduces capital requirements and production costs, especially for large-scale manufacturing, while enhancing the quality and efficiency of biopharmaceuticals through improved glycosylation processes. BioSourcing is committed to sustainability, aiming to minimize the carbon footprint associated with biotherapeutic production. The company boasts a team of leading scientists and international experts, supported by strategic partnerships with key players in the pharmaceutical and biotechnology sectors.

Atamyo Therapeutics is a biotechnology company based in Paris, France, established in 2020 by Stephane Degove and Isabelle Richard. The company is dedicated to developing innovative gene therapies aimed at treating neuromuscular diseases, particularly muscular dystrophies. Atamyo focuses on creating safer and more effective gene therapies by exploring novel approaches for gene replacement. Its research includes the development of specialized delivery systems designed to minimize side effects and enhance the restoration of normal physiological function in patients suffering from these challenging conditions. Through its advancements in gene therapy, Atamyo Therapeutics aims to improve the quality of life for individuals affected by neuromuscular disorders.

AltraTech designs biosensors and semiconductor chips for DNA testing to support food traceability in the agriculture sector. Incorporated in 2013 and based in Shannon, Ireland, the company also develops a portable viral detection device that combines enrichment and semiconductor techniques to match the sensitivity and specificity of PCR in a compact form, enabling rapid and accurate measurement of viral DNA, RNA, antigens, or antibodies for diagnostics.

Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.

Implicity develops a software-as-a-service remote monitoring platform for patients with connected pacemakers and defibrillators. The platform collects and analyzes data from cardiac electronic implants, using an artificial intelligence module to sort and summarize information and assess the criticality of alerts within the patient’s medical context. This enables cardiology and other healthcare professionals to automate remote monitoring, consolidate patient telemetry on a single platform, and support timely clinical decision-making to deliver high-quality care.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

Raidium is a Medtech company specializing in radiology-augmented technology. It is developing the first radiological foundation model, often referred to as the "GPT-4" of radiology, to simplify precision medicine. Raidium's deep learning algorithms analyze medical imaging data, providing AI-assisted diagnoses to radiologists via an integrated console. This enables earlier detection and management of serious conditions like cancer and cardiovascular diseases.

Cherry Biotech is a biomedical technology company that develops Organ on Chip instruments and microfluidic systems to culture and mimic human organs under physio-pathological conditions for drug discovery and personalized medicine. The company also offers temperature controllers for rapid temperature shifts and next-generation 3D cell culture technologies to recreate the human cell microenvironment, supporting drug development and toxicity assessment.

Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment to improve cancer patient outcomes. Their focus includes glioblastoma, ovarian, colorectal, and pancreatic cancers.

AltraTech designs biosensors and semiconductor chips for DNA testing to support food traceability in the agriculture sector. Incorporated in 2013 and based in Shannon, Ireland, the company also develops a portable viral detection device that combines enrichment and semiconductor techniques to match the sensitivity and specificity of PCR in a compact form, enabling rapid and accurate measurement of viral DNA, RNA, antigens, or antibodies for diagnostics.

Raidium is a Medtech company specializing in radiology-augmented technology. It is developing the first radiological foundation model, often referred to as the "GPT-4" of radiology, to simplify precision medicine. Raidium's deep learning algorithms analyze medical imaging data, providing AI-assisted diagnoses to radiologists via an integrated console. This enables earlier detection and management of serious conditions like cancer and cardiovascular diseases.

Implicity develops a software-as-a-service remote monitoring platform for patients with connected pacemakers and defibrillators. The platform collects and analyzes data from cardiac electronic implants, using an artificial intelligence module to sort and summarize information and assess the criticality of alerts within the patient’s medical context. This enables cardiology and other healthcare professionals to automate remote monitoring, consolidate patient telemetry on a single platform, and support timely clinical decision-making to deliver high-quality care.

BestHealth4U specializes in developing advanced adhesive technologies for medical applications. Their innovative solutions aim to prevent skin injuries, enhance healing, and improve overall patient health by transforming how bandages, dressings, and medical devices adhere to the skin.

Atamyo Therapeutics is a biotechnology company based in Paris, France, established in 2020 by Stephane Degove and Isabelle Richard. The company is dedicated to developing innovative gene therapies aimed at treating neuromuscular diseases, particularly muscular dystrophies. Atamyo focuses on creating safer and more effective gene therapies by exploring novel approaches for gene replacement. Its research includes the development of specialized delivery systems designed to minimize side effects and enhance the restoration of normal physiological function in patients suffering from these challenging conditions. Through its advancements in gene therapy, Atamyo Therapeutics aims to improve the quality of life for individuals affected by neuromuscular disorders.

BestHealth4U specializes in developing advanced adhesive technologies for medical applications. Their innovative solutions aim to prevent skin injuries, enhance healing, and improve overall patient health by transforming how bandages, dressings, and medical devices adhere to the skin.

Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment to improve cancer patient outcomes. Their focus includes glioblastoma, ovarian, colorectal, and pancreatic cancers.

Cherry Biotech is a biomedical technology company that develops Organ on Chip instruments and microfluidic systems to culture and mimic human organs under physio-pathological conditions for drug discovery and personalized medicine. The company also offers temperature controllers for rapid temperature shifts and next-generation 3D cell culture technologies to recreate the human cell microenvironment, supporting drug development and toxicity assessment.

Scope Biosciences develops molecular diagnostics leveraging CRISPR-Cas technology. It originated as a spin-off from Wageningen University & Research. The company aims to provide actionable nucleic acid detection in healthcare and agriculture with high specificity for single-nucleotide differences and sensitivity to trace genetic material, packaged in a format that can be used outside traditional laboratory settings to support on-site decision making by clinicians and agricultural professionals.

Gedea Biotech develops an antibiotic-free treatment for vaginal fungal infections using its substance GA101. This natural substance lowers pH, provides physical barrier protection, and inhibits biofilm formation. The company's first product is a topical treatment for vaginal fungal infections.

Qlucore is a prominent provider of advanced bioinformatics software designed for research and precision diagnostics in the life sciences. Founded in 2007 by researchers from Lund University in Sweden, the company aims to simplify the analysis of complex data generated in the fields of genetics and proteomics. Its flagship product, Qlucore Omics Explorer, is a user-friendly bioinformatics tool that enables researchers, technicians, and physicians to easily interpret and visualize large datasets. Additionally, Qlucore offers Qlucore Diagnostics, an AI-powered platform for multi-omics companion and precision diagnostics that integrates with various data-generating instruments. With a global presence, Qlucore serves customers in approximately 35 countries, including leading pharmaceutical companies, hospitals, and academic institutions.

Powerful Medical develops AI-driven cardiovascular care solutions. Its flagship product, PMcardio, improves heart attack detection accuracy, reducing mortality rates and enhancing hospital efficiency. With over 60,000 healthcare professionals on board, it has screened 1.1 million patients across leading health systems. The company's platform offers diagnosis reports, data collection, and personalized treatment plans using AI and machine learning algorithms.

BetaGlue Technologies SpA is a Milan-based company that specializes in the development and manufacture of medical devices designed for loco-regional radiation therapy targeting unresectable solid tumors. The company's innovative product features a proprietary beta-emitting biocompatible matrix, which facilitates the controlled administration of radionuclides directly into tumor masses. This technology not only enhances the effectiveness of cancer treatment but also plays a crucial role in preventing complications that can arise following procedures such as lung and liver biopsies. By focusing on localized therapies, BetaGlue Technologies aims to improve patient outcomes and advance the field of cancer treatment.

Novelrad is a privately held medical device company that specializes in innovative micro-sewing technology. The company has developed a suturing device designed for the closure of vascular and heart defects. This device allows for the deployment of various continuous suture patterns and multipoint purse string sutures, facilitating safe dilation at the start of surgical procedures and ensuring reliable closure at their conclusion. Through its advanced technology, Novelrad aims to enhance surgical outcomes and improve patient safety in cardiovascular surgeries.

Womed SAS, founded in 2018, is a medical device company that originated from research at Professor Garric's biopolymer lab at the University of Montpellier, France. The company focuses on addressing unmet medical needs in gynecologic surgery, particularly intrauterine adhesions, which can impact fertility and pregnancy. Womed develops insertable devices designed to act as mechanical barriers against adhesions, protecting the uterine cavity. These devices are engineered to break up, dissolve, and be naturally discharged without requiring intervention from healthcare professionals, thereby helping women reduce or prevent recurrent intrauterine adhesion formation and miscarriage.

HAWK Biosystems develops a companion diagnostics platform designed to quantify protein-protein interactions and their post-translational modifications in single-cell and fixed tissue samples. This platform offers built-in specificity while preserving the morphological integrity and cellular heterogeneity of tissues, enabling more precise treatment decisions in cancer, inflammation, and immune disorders.

O11 Biomedical GmbH is a spin-off from RWTH Aachen University's Institute for Applied Medical Engineering, specifically the Department of Biohybrids & Medical Textiles. The company specializes in liquid breathing technology aimed at treating hypercapnia, a condition characterized by elevated carbon dioxide levels in the blood. O11 Biomedical's innovative technology effectively binds carbon dioxide from intestinal fluid, facilitating its excretion through natural processes. By doing so, the company seeks to enhance both the survival and quality of life for patients afflicted with this respiratory condition.

AptaTargets is a biopharmaceutical company developing therapeutic applications based on aptamer technology. The company advances drug candidates from preclinical stages toward clinical development with the aim of reaching phase 2 trials. Its approach uses aptamers to recognize specific therapeutic targets, offering an antibody-like mechanism with potential advantages in precision and safety. The pipeline addresses inflammatory and neuroprotective indications, including conditions such as ischemic stroke, myocardial infarction, and autoimmune diseases, and seeks to modulate disease pathways through targeted molecular recognition.

Founded in 2017, Nectin Therapeutics develops novel monoclonal antibodies targeting the Nectin family of receptors and ligands. These antibodies aim to treat solid and hematological malignancies by modulating immune checkpoint mechanisms.

Powerful Medical develops AI-driven cardiovascular care solutions. Its flagship product, PMcardio, improves heart attack detection accuracy, reducing mortality rates and enhancing hospital efficiency. With over 60,000 healthcare professionals on board, it has screened 1.1 million patients across leading health systems. The company's platform offers diagnosis reports, data collection, and personalized treatment plans using AI and machine learning algorithms.

Hoba Therapeutics is focused on developing innovative biopharmaceuticals aimed at treating neuropathic pain and central nervous system disorders. The company is advancing a novel therapeutic protein designed to target specific cells, providing medical practitioners with effective and safe options for managing chronic pain and hearing loss. Through its research and development efforts, Hoba Therapeutics seeks to deliver disease-modifying treatments that enhance the quality of life for patients suffering from neuropathic pain.

Hephaistos Pharma is a biotechnology company developing an immunotherapy platform aimed at producing advanced oncology treatments. Its platform enhances commercialized antibodies by stimulating the immune system, turning 'cold' tumors into targets for immune response.

X-trodes develops scalable wireless electronic technology and analytics for biopotential signals, enabling advanced electrophysiological monitoring. Its solution combines wearable hardware with automated, high-resolution analysis to support clinical evaluation and treatment across brain, eye, muscle, and heart signals. The technology is designed to track physiological activity during sleep and everyday tasks, providing objective measurements that can inform medical decisions and help improve patients’ quality of life. By integrating sensors and analytics in a cohesive platform, X-trodes aims to make continuous biopotential monitoring practical in routine healthcare settings, offering clinicians and patients insights into neural, ocular, muscular, and cardiovascular health through a single, scalable system.

X-trodes develops scalable wireless electronic technology and analytics for biopotential signals, enabling advanced electrophysiological monitoring. Its solution combines wearable hardware with automated, high-resolution analysis to support clinical evaluation and treatment across brain, eye, muscle, and heart signals. The technology is designed to track physiological activity during sleep and everyday tasks, providing objective measurements that can inform medical decisions and help improve patients’ quality of life. By integrating sensors and analytics in a cohesive platform, X-trodes aims to make continuous biopotential monitoring practical in routine healthcare settings, offering clinicians and patients insights into neural, ocular, muscular, and cardiovascular health through a single, scalable system.

PannTheraPi is a biotechnology company focused on developing therapies for brain and nervous system diseases. It operates a discovery program grounded in human tissue studies and seeks to identify novel targets and develop Pannexin channel blocker drugs. By pursuing repurposed, safety-validated compounds, it aims to expand treatment options and accelerate access to medicines addressing unmet neurological needs.

Thirona is a software company that develops AI-powered medical imaging analysis tools and provides image analysis services for the healthcare industry. Its automated tools support the analysis of thoracic CT scans, chest X-rays, and retinal images, delivering accurate and repeatable measurements to help hospitals detect and mitigate diseases. The company offers software solutions and certified image analysis services that streamline imaging workflows and improve diagnostic precision.

Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of an innovative silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have experienced nerve damage due to trauma or cancer surgery. This approach eliminates the risks associated with traditional autograft treatments, which often lead to significant morbidity. By providing healthcare professionals with an effective alternative, Newrotex aims to enhance patient outcomes in the treatment of peripheral nerve injuries.

GeneCode AS creates new disease-modifying pharmaceuticals.

Celtic Biotech is a biotechnology company focused on developing innovative therapies for the treatment of solid cancers and pain in humans. Co-founded by John Reid, the company utilizes specialized receptor-binding proteins derived from snake venom to create its therapeutic products. These novel candidate therapies aim to enhance patient survival rates, improve quality of life, and reduce the overall costs of cancer treatment. By leveraging unique biological mechanisms, Celtic Biotech addresses significant medical challenges in oncology and pain management.

Genewity B.V. is a biotech company that works closely with LUmc to build on the achievements of our scientific and business teams in cell and gene therapies.

Picterus is developing an app to diagnose jaundice in newborns, aiming to reduce the global infant mortality associated with this condition. The platform uses a patented color calibration card and smartphone camera for accurate image capture, providing healthcare professionals and caregivers with a reliable tool for early detection and timely intervention.

GeneCode AS creates new disease-modifying pharmaceuticals.

Luminate Medical specializes in developing innovative medical devices aimed at preventing hair loss during chemotherapy. Recognizing the significant impact of hair loss on patients' self-esteem, the company focuses on utilizing advanced medical technology to protect this essential element of personality.

Hooke Bio Ltd. is a biotechnology company based in Shannon, Ireland, focused on developing microfluidic technologies for drug screening and related applications. Founded in 2014, the company has created a fully integrated high-throughput screening system that utilizes 3D microtissues, such as spheroids and organoids, to generate biological data. This innovative, patent-protected technology aims to reduce reliance on animal models in preclinical studies and accelerate the drug development process. By enabling pharmaceutical companies and clinicians to develop more accurate disease models and optimize treatments based on individual patient samples, Hooke Bio enhances the ability to test and repurpose drugs effectively, ultimately improving patient care and outcomes.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Xenothera is a biotechnology company that specializes in xenotherapy, focusing on the development of innovative immunological treatments. Utilizing a unique technological platform, Xenothera combines expertise in animal genetics with advanced immunology processes to create new therapeutic approaches for various medical conditions, including immunomodulation and infectious diseases. The company is particularly noted for its development of hyperimmune polyclonal sera, which represents a new generation of passive immunotherapy. By controlling the entire process—from the selection of immunogens to the purification of immunoglobulins—Xenothera is able to accelerate the development and market authorization of its therapies, thereby facilitating timely access to novel treatments for patients.

ResoTher Pharma is a privately held biotechnology company based in Copenhagen, Denmark. The company specializes in developing peptide-based drugs derived from Annexin A1, an endogenous immunomodulator. These drugs are designed as resolution therapies for diseases where neutrophil-driven inflammation is a key pathological factor. ResoTher Pharma's primary focus is on addressing cardiovascular and inflammatory disorders that have significant unmet medical needs. Their patented peptide drugs target a G-protein coupled receptor expressed on leukocytes, aiming to mimic the body's natural response to resolving inflammation and promoting tissue repair.

ReST Therapeutics is a clinical biotechnology company focused on developing innovative therapies for complex central nervous system (CNS) disorders. Utilizing its patented medication candidate, the company aims to create treatments that selectively target NMDA receptors, with the intention of addressing conditions such as post-traumatic stress disorder (PTSD) and Alzheimer's disease. By advancing its candidate through non-clinical testing, ReST Therapeutics seeks to improve the efficacy of cognitive preservation and provide protection against neurotoxicity, thereby enhancing therapeutic outcomes for patients suffering from these debilitating neural disorders.

Nimble Diagnostics is a company that offers a range of DNA testing services, including paternity testing, prenatal gender testing, family relationship testing, ancestry DNA testing, and DNA art. In addition to these services, the company provides cancer nutraceuticals, aiming to support patients' health and well-being. Nimble Diagnostics leverages the internet to deliver its offerings globally at affordable prices, maintaining a commitment to accessible molecular diagnostics. The company also focuses on developing medical monitoring devices that enhance patient care, particularly for individuals with medical implants. These devices enable continuous, non-invasive monitoring, allowing healthcare providers to transition from reactive to proactive care, thereby reducing clinical complications associated with implanted stents.

Founded in 2017, SolasCure is a biotechnology company based in Wales, UK. It specializes in developing innovative hydrogel treatments for patients with chronic wounds. Its flagship product, Aurase, facilitates wound debridement, removing dead or infected tissue to enhance healing.

Strolll is a digital health company focused on improving mobility for people with neurological disorders. It develops a B2B digital therapeutics platform that delivers clinically validated rehabilitation software on off-the-shelf augmented reality glasses. The platform supports both in-clinic (synchronous) and at-home (asynchronous) therapy, enabling rehabilitation clinics to scale services, improve access, and reduce the cost of neurorehabilitation. By personalizing therapy, the solution aims to increase patient adherence and outcomes while streamlining administrative processes and delivering meaningful data to clinics.

MultiplexDX develops accurate, specific, quantifiable diagnostic tests combining molecular biology and histopathological methods. Based in Kosice, Slovakia and Gaithersburg, Maryland, USA, it aims to improve cancer diagnosis and treatment.

MaxiVAX is a Swiss clinical-stage biotechnology company developing personalized cancer immunotherapies. Its lead product, MVX-ONCO-1, is an advanced therapeutic product for various tumors, currently in phase I trials.